NOVOZYMES A/S/S (OTCMKTS:NVZMY) Stock Price Crosses Above 50 Day Moving Average of $43.34

NOVOZYMES A/S/S (OTCMKTS:NVZMY)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $43.34 and traded as high as $43.52. NOVOZYMES A/S/S shares last traded at $43.20, with a volume of 15,985 shares trading hands.

Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised NOVOZYMES A/S/S from an “underweight” rating to a “neutral” rating in a research note on Monday, August 19th. Zacks Investment Research raised NOVOZYMES A/S/S from a “sell” rating to a “hold” rating in a research note on Tuesday, August 20th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $54.00.

The firm has a market capitalization of $12.83 billion, a P/E ratio of 24.70, a price-to-earnings-growth ratio of 2.04 and a beta of 0.76. The firm has a 50 day moving average price of $43.26 and a 200-day moving average price of $45.96. The company has a current ratio of 1.22, a quick ratio of 0.71 and a debt-to-equity ratio of 0.05.

NOVOZYMES A/S/S Company Profile (OTCMKTS:NVZMY)

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.

Further Reading: What is an economic bubble?

Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.